Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively degenerate. However, long-term analysis of human iPS cell-derived dopaminergic neurons in primate PD models has never been performed to our knowledge. Here we show that human iPS cell-derived dopaminergic progenitor cells survived and functioned as midbrain dopaminergic neurons in a primate model of PD (Macaca fascicularis) treated with the neurotoxin MPTP. Score-based and video-recording analyses revealed an increase in spontaneous movement of the monkeys after transplantation. Histological studies showed that the mature dopaminergic neurons extended dense neurites into the host striatum; this effect was consistent regardless of whether the cells were derived from patients with PD or from healthy individuals. Cells sorted by the floor plate marker CORIN did not form any tumours in the brains for at least two years. Finally, magnetic resonance imaging and positron emission tomography were used to monitor the survival, expansion and function of the grafted cells as well as the immune response in the host brain. Thus, this preclinical study using a primate model indicates that human iPS cell-derived dopaminergic progenitors are clinically applicable for the treatment of patients with PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Morizane et al. and Kikuchi et al. both showed that an improvement of engraftment and reduced immune reaction were observed using MHC matching of iPSC-derived dopaminergic neurons in unlesioned non-human primates [98,99].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [99]
In the citing paper
“A comprehensive study of human iPSC-derived dopamine neuron progenitor cells expressing specific markers of the neural floor plate (CORIN+; FOXA2+; TUJ1+; PAX6−) and transplanted into a monkey model of Parkinson’s disease showed stronger evidence of behavioural benefits, of cellular integration of mature dopamine neurons within the putamen, and of extension of their dense neurites into the host st”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
In the citing paper
“Most of the transplanted cells expressed FOXA2 and a third expressed tyrosine hydroxylase consistent with mature functional dopamine neurons.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
Citations
Cites
Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630
Jenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
Fast robust automated brain extraction
Smith, S. M. (2002) · Human Brain Mapping · doi:10.1002/hbm.10062 · Cited by 10,496
Zhang, Y., Brady, M., & Smith, S. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.906424 · Cited by 6,982
A global optimisation method for robust affine registration of brain images
Jenkinson, M., & Smith, S. (2001) · Medical Image Analysis · doi:10.1016/s1361-8415(01)00036-6 · Cited by 6,872
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,907
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Cited by
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges
Yamanaka, S. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.09.014 · Cited by 1,213
An in vivo model of functional and vascularized human brain organoids
Mansour, A. A., Gonçalves, J. T., Bloyd, C. W., Li, H., Fernandes, S., Quang, D., Johnston, S., Parylak, S. L., Jin, X., & Gage, F. H. (2018) · Nature Biotechnology · doi:10.1038/nbt.4127 · Cited by 1,211
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson’s Disease
Schweitzer, J. S., Song, B., Herrington, T. M., Park, T.-Y., Lee, N., Ko, S., Jeon, J., Cha, Y., Kim, K., Li, Q., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915872 · Cited by 542
Transcription factor-mediated differentiation of human iPSCs into neurons
Fernandopulle, M. S., Prestil, R., Grunseich, C., Wang, C., Gan, L., & Ward, M. E. (2018) · Current Protocols in Cell Biology · doi:10.1002/cpcb.51 · Cited by 461
Oxidative stress and regulated cell death in Parkinson’s disease
Dionísio, P. A., Amaral, J. D., & Rodrigues, C. M. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101263 · Cited by 424
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J. K., Todani, M., Nakagawa, M., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00039.2017 · Cited by 368
Self-citationDoi, D., Magotani, H., Kikuchi, T., Ikeda, M., Hiramatsu, S., Yoshida, K., Amano, N., Nomura, M., Umekage, M., Morizane, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17165-w · Cited by 350
Self-citationHuman Trials of Stem Cell-Derived Dopamine Neurons for Parkinson’s Disease: Dawn of a New Era
Barker, R. A., Parmar, M., Studer, L., & Takahashi, J. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.09.014 · Cited by 329
“…it is critical to mention that the protocols employed in all the studies within GForce-PD have worked well in a number of in vivo studies with no tumor formation or uncontrolled growth (Grealish et al., 2014; Kikuchi et al., 2017; Kirkeby et al., 2012; Kriks et al., 2011; Steinbeck et al., 2015).”
BackgroundResultSelf-citationChen, H.-X., Liang, F.-C., Gu, P., Xu, B.-L., Xu, H.-J., Wang, W.-T., Hou, J.-Y., Xie, D.-X., Chai, X.-Q., & An, S.-J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2473-5 · Cited by 319
The future of stem cell therapies for Parkinson disease
Parmar, M., Grealish, S., & Henchcliffe, C. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0257-7 · Cited by 306
Self-citationEmerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Challenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment
Zeng, X.-S., Geng, W.-S., & Jia, J.-J. (2018) · ASN Neuro · doi:10.1177/1759091418777438 · Cited by 275
The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration
Azam, S., Haque, M. E., Balakrishnan, R., Kim, I.-S., & Choi, D.-K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683459 · Cited by 255
“…potential of inflammatory pathways, a better understanding of the neuroprotective role played by TNF-α and NF-κB remains necessary, and new models must be developed that are able to recapitulate microglia-induced neurodegenerative phenomena in vivo (Klünemann et al., 2005; Ransohoff, 2016).”
BackgroundAdvances in stem cell research and therapeutic development
De Luca, M., Aiuti, A., Cossu, G., Parmar, M., Pellegrini, G., & Robey, P. G. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0344-z · Cited by 239
Self-citationStem Cells in the Treatment of Disease
Blau, H. M., & Daley, G. Q. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1716145 · Cited by 228
New approaches for brain repair-from rescue to reprogramming
Barker, R. A., Götz, M., & Parmar, M. (2018) · Nature · doi:10.1038/s41586-018-0087-1 · Cited by 214
Self-citationPhase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease
Sawamoto, N., Doi, D., Nakanishi, E., Sawamura, M., Kikuchi, T., Yamakado, H., Taruno, Y., Shima, A., Fushimi, Y., Okada, T., et al. (2025) · Nature · doi:10.1038/s41586-025-08700-0 · Cited by 202
“These cells produced DA in the brains of non-human primate PD models and improved their motor symptoms 12 .”
InfluentialSelf-citationZheng, P., Wu, J., Zhang, H., Perry, S. W., Yin, B., Tan, X., Chai, T., Liang, W., Huang, Y., Li, Y., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0744-2 · Cited by 205
“matched controls: based on the data of previous nonhuman primate studies [28, 29], and our work on behavioral and biochemical measures in M.”
MethodPluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Kirkeby, A., Main, H., & Carpenter, M. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2024.12.005 · Cited by 196
Omole, A. E., & Fakoya, A. O. J. (2018) · PeerJ · doi:10.7717/peerj.4370 · Cited by 204
“The more recent long-term study involving the application of human iPSC-derived dopaminergic neurons in primate Parkinson’s disease (PD) models at the Center for iPS Cell Research and Application, Kyoto University, Japan, reveals that human iPSCs are clinically applicable for the treatment of patients with PD (Kikuchi…”
BackgroundiPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
Okano, H., & Morimoto, S. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.01.007 · Cited by 202
Advancing cell therapy for neurodegenerative diseases
Temple, S. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.03.017 · Cited by 198
Parkinson's disease in the Western Pacific Region
Lim, S.-Y., Tan, A. H., Ahmad-Annuar, A., Klein, C., Tan, L. C. S., Rosales, R. L., Bhidayasiri, R., Wu, Y.-R., Shang, H.-F., Evans, A. H., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30195-4 · Cited by 201
Current state of stem cell-based therapies: an overview
Aly, R. M. (2020) · Stem Cell Investigation · doi:10.21037/sci-2020-001 · Cited by 201
Kim, T. W., Piao, J., Koo, S. Y., Kriks, S., Chung, S. Y., Betel, D., Socci, N. D., Choi, S. J., Zabierowski, S., Dubose, B. N., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.01.005 · Cited by 210
“…of in vitro hPSCderived mDA neurons in mouse, rat or monkey models of PD required the development of floor plate derived midbrain dopamine neuron differentiation protocols (Doi et al., 2014; Kikuchi et al., 2017; Kirkeby et al., 2012; Kriks et al., 2011; Sundberg et al., 2013; Xi et al., 2012).”
BackgroundCellular and Molecular Basis of Neurodegeneration in Parkinson Disease
Zeng, X.-S., Geng, W.-S., Jia, J.-J., Chen, L., & Zhang, P.-P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00109 · Cited by 193
iPS cell-based therapy for Parkinson's disease: A Kyoto trial
Takahashi, J. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.06.002 · Cited by 192
“Furthermore, we conducted an in vivo study using cynomolgus monkey models as a simulation of a clinical trial [23].”
MethodSelf-citationSong, B., Cha, Y., Ko, S., Jeon, J., Lee, N., Seo, H., Park, K.-J., Lee, I.-H., Lopes, C., Feitosa, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130767 · Cited by 189
“elegantly showed that hiPSC-derived DA cells can survive and ameliorate motor behaviors in MPTP-lesioned monkey models (65), but direct comparison of those results with our study is hindered by the different species platform used.”
ResultGenetic predispositions of Parkinson’s disease revealed in patient-derived brain cells
Tran, J., Anastacio, H., & Bardy, C. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0110-8 · Cited by 176
Ioannidis, J. P. A., Kim, B. Y. S., & Trounson, A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0314-y · Cited by 175
Pluripotent stem cell-based therapy for Parkinson’s disease: Current status and future prospects
Sonntag, K.-C., Song, B., Lee, N., Jung, J. H., Cha, Y., Leblanc, P., Neff, C., Kong, S. W., Carter, B. S., Schweitzer, J., et al. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.04.005 · Cited by 143
Yoshida, S., Kato, T. M., Sato, Y., Umekage, M., Ichisaka, T., Tsukahara, M., Takasu, N., & Yamanaka, S. (2023) · Med · doi:10.1016/j.medj.2022.10.003 · Cited by 134
Wang, Y.-K., Zhu, W.-W., Wu, M.-H., Wu, Y.-H., Liu, Z.-X., Liang, L.-M., Sheng, C., Hao, J., Wang, L., Li, W., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.05.010 · Cited by 132
“This result is consistent with previous studies in rodents and primates (Doi et al., 2012; Grealish et al., 2014; Hallett et al., 2015; Kikuchi et al., 2017).”
ResultDirect neuronal reprogramming: Fast forward from new concepts toward therapeutic approaches
Bocchi, R., Masserdotti, G., & Götz, M. (2022) · Neuron · doi:10.1016/j.neuron.2021.11.023 · Cited by 130
Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys
Tao, Y., Vermilyea, S. C., Zammit, M., Lu, J., Olsen, M., Metzger, J. M., Yao, L., Chen, Y., Phillips, S., Holden, J. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01257-1 · Cited by 124
Emerging Treatment Approaches for Parkinson’s Disease
Stoker, T. B., Torsney, K., & Barker, R. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00693 · Cited by 148
Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells
Stoddard-Bennett, T., & Reijo Pera, R. (2019) · Cells · doi:10.3390/cells8010026 · Cited by 127
“Similarly, postmortem analyses of iPSC transplants in non‐human primate models reveal robust growth, proliferation and integration into existing neural networks [99,100].”
BackgroundInfluentialLaperle, A., Sances, S., Yucer, N., Dardov, V. J., Garcia, V. J., Ho, R., Fulton, A., Jones, M. R., Roxas, K., Avalos, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0739-1 · Cited by 132
The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment
Mosaddeghi-Heris, R., Shirvaliloo, M., Abbaspour‐Aghdam, S., Hazrati, A., Shariati, A., Youshanlouei, H. R., Jadidi‐Niaragh, F., Valizadeh, H., & Ahmadi, M. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03050-4 · Cited by 128
“As a result, several SNpc cell therapy trials in animals transplant dopaminergic neurons ectopically into striatums [121, 122].”
BackgroundFeng, G., Jensen, F. E., Greely, H. T., Okano, H., Treue, S., Roberts, A. C., Fox, J. G., Caddick, S., Poo, M.-M., Newsome, W. T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006515117 · Cited by 117
Tiklová, K., Nolbrant, S., Fiorenzano, A., Björklund, Å. K., Sharma, Y., Heuer, A., Gillberg, L., Hoban, D. B., Cardoso, T., Adler, A. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16225-5 · Cited by 114
Self-citationThe nonhuman primate neuroimaging and neuroanatomy project
Hayashi, T., Hou, Y., Glasser, M. F., Autio, J. A., Knoblauch, K., Inoue‐Murayama, M., Coalson, T., Yacoub, E. S., Smith, S. M., Kennedy, H., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117726 · Cited by 122
Self-citationAdler, A. F., Cardoso, T., Nolbrant, S., Mattsson, B., Hoban, D. B., Jarl, U., Wahlestedt, J. N., Grealish, S., Björklund, A., & Parmar, M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.058 · Cited by 109
“A number of studies have shown that transplanted fetal- and stem-cell-derived DA neurons are phenotypically similar and that they survive, innervate, and function with equal potency after transplantation in preclinical models of PD (Grealish et al., 2014; Kikuchi et al., 2017; Kriks et al., 2011).”
BackgroundSelf-citationExtracellular Vesicles as Nanotherapeutics for Parkinson’s Disease
Leggio, L., Paternò, G., Vivarelli, S., L’Episcopo, F., Tirolo, C., Raciti, G., Pappalardo, F., Giachino, C., Caniglia, S., Serapide, M. F., et al. (2020) · Biomolecules · doi:10.3390/biom10091327 · Cited by 100
“On the contrary, other reports demonstrated that iPSC-derived DAergic progenitor cells transplanted in primate PD models survived and worked as DAergic neurons without any tumor formation in the brain, therefore demonstrating their clinical relevance for transplantation in PD patients [206,207].”
ResultLee, S., Huh, J. Y., Turner, D. M., Lee, S., Robinson, J., Stein, J. E., Shim, S. H., Hong, C. P., Kang, M. S., Nakagawa, M., et al. (2018) · Stem Cells · doi:10.1002/stem.2865 · Cited by 99
Self-citationPluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities
Kim, T. W., Koo, S. Y., & Studer, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00729 · Cited by 107
“D opam ine N eurons for C ellTherapy TABLE 1 | Continued Group Cell Source DIV at the time of injection Cell Dosage for graft Animal PD Model (Lesioning Method) Transplant Location Cell Quality Control Sorting Strategy (N/Y) mDA Subtypes Other neuronal types/proliferating cells References Kim hiPSC Day 28 100,000– 300…”
BackgroundMethodInfluentialPesticides and Parkinson’s disease: Current and future perspective
Islam, M. S., Azim, F., Saju, H., Zargaran, A., Shirzad, M., Kamal, M., Fatema, K., Rehman, S., Azad, M. A. M., & Ebrahimi‐Barough, S. (2021) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2021.101966 · Cited by 109
Gantner, C. W., de Luzy, I. R., Kauhausen, J. A., Moriarty, N., Niclis, J. C., Bye, C. R., Penna, V., Hunt, C. J., Ermine, C. M., Pouton, C. W., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.01.010 · Cited by 93
Induced cardiomyocytes-integrated conductive microneedle patch for treating myocardial infarction
Sun, L., Zhu, X., Zhang, X., Chen, G., Bian, F., Wang, J., Zhou, Q., Wang, D., & Zhao, Y. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.128723 · Cited by 93
Stem Cell-Based Therapies for Parkinson Disease
Liu, Z., & Cheung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218060 · Cited by 104
“hPSC-derived DA progenitor cells were demonstrated to survive, mature, and function with good outcomes as midbrain DA neurons in an MPTP-induced primate PD model without formation of tumors in the brain for at least two years [107,108].”
BackgroundReplacing what’s lost: a new era of stem cell therapy for Parkinson’s disease
Fan, Y., Winanto, W., & Ng, S. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-019-0180-x · Cited by 91
Yuan, X., Schröter, M., Obien, M. E. J., Fiscella, M., Gong, W., Kikuchi, T., Odawara, A., Noji, S., Suzuki, I., Takahashi, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18620-4 · Cited by 89
Self-citationWu, J., Kung, J., Dong, J., Chang, L., Xie, C., Habib, A., Hawes, S., Yang, N., Chen, V., Liu, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.095 · Cited by 87
Microfluidics for Neuronal Cell and Circuit Engineering
Habibey, R., Rojo Arias, J. E., Striebel, J., & Busskamp, V. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00212 · Cited by 85
Clinical Translation of Pluripotent Stem Cell Therapies: Challenges and Considerations
Desgres, M., & Menasché, P. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.10.001 · Cited by 84
Kawai, M., Imaizumi, K., Ishikawa, M., Shibata, S., Shinozaki, M., Shibata, T., Hashimoto, S., Kitagawa, T., Ago, K., Kajikawa, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110019 · Cited by 92
Micro- and nanotechnology approaches to improve Parkinson's disease therapy
Torres-Ortega, P. V., Saludas, L., Hanafy, A. S., Garbayo, E., & Blanco‐Prieto, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.036 · Cited by 88
Cui, W., Guo, Z., Chen, X., Yan, R., Ma, W., Yang, X., & Lin, Y. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.10.027 · Cited by 90
Towards stem cell based therapies for Parkinson's disease
Parmar, M. (2018) · Development · doi:10.1242/dev.156117 · Cited by 79
Self-citationWu, Y.-Y., Chiu, F.-L., Yeh, C.-S., & Kuo, H.-C. (2019) · Open Biology · doi:10.1098/rsob.180177 · Cited by 75
Gao, X., Cheng, W., Zhang, X., Zhou, Z., Ding, Z., Zhou, X., Lü, Q., & Kaplan, D. L. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c19229 · Cited by 78
TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons
Kim, T. W., Koo, S. Y., Rießland, M., Chaudhry, F. F., Kolisnyk, B., Cho, H., Russo, M. V., Saurat, N. G., Mehta, S., Garippa, R. J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.030 · Cited by 90
Cell therapy for central nervous system disorders: Current obstacles to progress
Yasuhara, T., Kawauchi, S., Kin, K., Morimoto, J., Kameda, M., Sasaki, T., Bonsack, B., Kingsbury, C., Tajiri, N., Borlongan, C. V., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13247 · Cited by 74
Olesen, M. A., Villavicencio-Tejo, F., & Quintanilla, R. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00308-y · Cited by 88
“From this point, direct conversion technologies have increased rapidly, where they are seen as a helpful approach to generating different cell types from human patients and donors for disease modelling, potential regeneration [207, 208], drug development, and offering advantage of safety [243, 265], or even for cell r…”
BackgroundTargeting the Dopaminergic System in Autoimmunity
Vidal, P. M., & Pacheco, R. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09834-5 · Cited by 72
Ford, E., Pearlman, J., Ruan, T., Manion, J., Waller, M. A., Neely, G. G., & Caron, L. (2020) · Cells · doi:10.3390/cells9112517 · Cited by 74
“Vector- and transgene-free hiPSC-NPCs were transplanted into a model of stroke [30] or PD [21,24].”
BackgroundMethodCardoso, T., Adler, A. F., Mattsson, B., Hoban, D. B., Nolbrant, S., Wahlestedt, J. N., Kirkeby, A., Grealish, S., Björklund, A., & Parmar, M. (2018) · The Journal of Comparative Neurology · doi:10.1002/cne.24500 · Cited by 74
“The ability of hPSC-derived neurons to extend axons across large distances sufficient to reinnervate the human brain has been modeled experimentally using intrastriatal transplantation in non-human primates (Kikuchi et al., 2017; Morizane et al., 2017; Wakeman et al., 2017).”
BackgroundSelf-citationThe Challenge of Bringing iPSCs to the Patient
Ortuño‐Costela, M. D. C., Cerrada, V., García‐López, M., & Gallardo, M. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246305 · Cited by 76
Wu, J., Li, Y., Huang, Y., Liu, L., Zhang, H., Nagy, C., Tan, X., Cheng, K., Liu, Y., Pu, J., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01379-4 · Cited by 77
Metformin's Mechanisms in Attenuating Hallmarks of Aging and Age-Related Disease
Cheng, F., Liu, Y.-L., Du, J., & Lin, J. (2022) · Aging and Disease · doi:10.14336/ad.2021.1213 · Cited by 87
Nie, L., Yao, D., Chen, S., Wang, J., Pan, C., Wu, D., Liu, N., & Tang, Z. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01532-9 · Cited by 81
“After implantation, some of these preconditioned NSCs could survive in the PD animal model and exhibit a phenotype of nigra DAergic neurons, with increased dopamine levels [60, 67, 73, 76, 81, 82, 84, 85, 178].”
BackgroundUtility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
Song, P., Chen, S. X., Yan, Y. H., Pinto, A., Cheng, L. Y., Dai, P., Patel, A. A., & Zhang, D. Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00713-0 · Cited by 76
Generation of caudal-type serotonin neurons and hindbrain-fate organoids from hPSCs
Valiulahi, P., Vidyawan, V., Puspita, L., Oh, Y., Juwono, V. B., Sittipo, P., Friedlander, G., Yahalomi, D., Sohn, J., Lee, Y. K., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.06.006 · Cited by 70
“This strategy has also been applied to sort midbrain dopamine neurons using CORIN, a floor-plate-specific cell surface marker (Kikuchi et al., 2017).”
MethodBrain repair mechanisms after cell therapy for stroke
Rust, R., Nih, L. R., Liberale, L., Yin, H. R., Amki, M. E., Ong, L. K., & Zloković, B. V. (2024) · Brain · doi:10.1093/brain/awae204 · Cited by 76
“As an example, iPSC-derived dopaminergic precursor cells and iPSC-derived retinal epithelial cells were found to be safe and effective in treating Parkinson’s disease 157,158 and age-related macular degeneration.”
Cecerska-Heryć, E., Pękała, M., Serwin, N., Gliźniewicz, M., Grygorcewicz, B., Michalczyk, A., Heryć, R., Budkowska, M., & Dołęgowska, B. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01344-6 · Cited by 59
Hoban, D. B., Shrigley, S., Mattsson, B., Breger, L., Jarl, U., Cardoso, T., Nelander-Wahlestedt, J., Luk, K. C., Björklund, A., & Parmar, M. (2020) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2001305117 · Cited by 46
Self-citationXu, P., He, H., Gao, Q., Zhou, Y., Wu, Z., Zhang, X., Sun, L.-Y., Hu, G., Guan, Q., You, Z., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156768 · Cited by 66
“The low mDA neuron ratio in grafts has been a major obstacle to PD cell therapy (10, 16, 18, 26, 51, 52).”
Bordoni, M., Rey, F., Fantini, V., Pansarasa, O., Giulio, A. M. D., Carelli, S., & Cereda, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123972 · Cited by 65
Velikic, G. S., Maric, D. M., Marić, D., Šupić, G., Puletić, M., Dulić, O., & Vojvodić, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020993 · Cited by 77
“For example, iPSC-derived astrocytes might support motor neurons in amyotrophic lateral sclerosis (ALS)—a neurodegenerative disease that affects motor neurons—or replace dopaminergic neurons that produce dopamine, a neurotransmitter involved in movement control in PD [99,100].”
BackgroundCell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Sulfide regulation and catabolism in health and disease
Hou, Y., Lv, B., Du, J., Ye, M., Jin, H., Yi, Y., & Huang, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02231-w · Cited by 75
Stem cell therapy for Parkinson’s disease: safety and modeling
Stoddard-Bennett, T., & Pera, R. A. R. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.264446 · Cited by 61
“In a longitudinal study following chemical induction of PD, non-human primates two years after transplantation of human iPSC cells still demonstrated significant improvement (Kikuchi et al., 2017).”
BackgroundNext‐generation disease modeling with direct conversion: a new path to old neurons
Traxler, L., Edenhofer, F., & Mertens, J. (2019) · FEBS Letters · doi:10.1002/1873-3468.13678 · Cited by 56
Barbuti, P. A., Barker, R. A., Brundin, P., Przedborski, S., Papa, S. M., Kalia, L. V., & Mochizuki, H. (2021) · Movement Disorders · doi:10.1002/mds.28628 · Cited by 61
“They also found that a minimum of 16,000 dopaminergic neurons was needed to produce significant motor function improvement.(55) Overall, most groups estimate that the number of cells that will be used will be in the order of 2–4 million per side of the brain.”
BackgroundTakahashi, J. B. (2019) · Regenerative Medicine · doi:10.2217/rme-2018-0158 · Cited by 55
Self-citationKim, S. W., Woo, H.-J., Kim, E. H., Kim, H. S., Suh, H. N., Kim, S.-H., Song, J. J., Wulansari, N., Kang, M., Choi, S., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102086 · Cited by 63
The Application of Brain Organoids in Assessing Neural Toxicity
Fan, P., Wang, Y., Xu, M., Han, X., & Liu, Y. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.799397 · Cited by 57
“Studies have verified the feasibility of hiPSCs for predicting neural toxicity by validating the effects of well-known toxicants, such as retinoic acid (Colleoni et al., 2011) and ethanol (Kim et al., 2014, 2016), on the brain.”
BackgroundRobust detection of undifferentiated iPSC among differentiated cells
Sekine, K., Tsuzuki, S., Yasui, R., Kobayashi, T., Ikeda, K., Hamada, Y., Kanai, E., Camp, J. G., Treutlein, B., Ueno, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66845-6 · Cited by 55
Challenges in the clinical advancement of cell therapies for Parkinson’s disease
Skidmore, S., & Barker, R. A. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00987-y · Cited by 59
“For PD, this has led to research groups using the H9 ES cell line 61 ; allogeneic induced pluripotent stem cell (iPSC) lines 62 , the ESC RC17 line 63 and even autologous iPSC lines 64 , as well as parthenogenetic stem cells 65 (Table 2).”
BackgroundResultInfluentialHaenseler, W., & Rajendran, L. (2019) · Stem Cells · doi:10.1002/stem.2995 · Cited by 52
Kashpur, O., Smith, A., Gerami‐Naini, B., Maione, A. G., Calabrese, R., Tellechea, A., Theocharidis, G., Liang, L., Pastar, I., Tomic‐Canic, M., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801059 · Cited by 55
“Our findings are supported by recent studies showing a similar “phenotypic convergence” in iPSC-derived dopaminergicneurons reprogrammedfromsporadicParkinson’s disease (56) and iPSC-derived fibroblasts reprogrammed from scleroderma (57).”
ResultSynthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons
Xue, Y., Zhan, X., Sun, S., Karuppagounder, S. S., Xia, S., Dawson, V. L., Dawson, T. M., Laterra, J., Zhang, J., & Ying, M. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0036 · Cited by 62
Park, S. H., Park, C. W., Eom, J. H., Jo, M.-Y., Hur, H., Choi, S. K., Lee, J. S., Nam, S. T., Jo, K.-S., Oh, Y. W., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.009 · Cited by 54
Systems level analysis of sex-dependent gene expression changes in Parkinson’s disease
Tranchevent, L.-C., Halder, R., & Glaab, E. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00446-8 · Cited by 79
Urso, D., Chaudhuri, К. R., Qamar, M. A., & Jenner, P. G. (2020) · CNS Drugs · doi:10.1007/s40263-020-00769-7 · Cited by 60
Midbrain Dopaminergic Neuron Development at the Single Cell Level: In vivo and in Stem Cells
Ásgrímsdóttir, E. S., & Arenas, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00463 · Cited by 61
“The information gained from studying mDA neuron development, whether that be in the murine or human VM, has in recent years led to the development of several protocols that direct the differentiation of hPSCs into functional mDA neurons capable of rescuing motor deficits in rodent and non-human primate models of PD (K…”
Method
Metadata
- Authors
- Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., Mizuma, H., Takara, S., Takahashi, R., Inoue, H., Morita, S., Yamamoto, M., Okita, K., Nakagawa, M., Parmar, M., & Takahashi, J.
- Affiliations
- Kyoto University (JP)
- RIKEN (JP)
- Lund University (SE)
- Corresponding author
- Takahashi, Jun
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7669
- Pages
- 592-596
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2751466955
- Cited by
- 702
- References
- 48
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 74 · 2023: 69 · 2022: 91 · 2021: 89 · 2020: 123 · 2019: 88 · 2018: 75 · 2017: 6
- FWCI
- 32.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (15H02502, 15H02540, 16H03306, 15K12779, 16H03300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, dopaminergic neurons, induced pluripotent stem cells, cell transplantation, nonhuman primate model, Macaca fascicularis, MPTP-induced neurotoxicity, midbrain dopaminergic neurons, spontaneous movement, neurite outgrowth, corin, tumor formation, cell survival, cell tracking, immune response, cell therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Cell Survival, Disease Models, Animal, Humans, Macaca fascicularis, Magnetic Resonance Imaging, Male, Mesencephalon, Movement, Parkinson Disease, Serine Endopeptidases, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurites, Neostriatum, Regenerative Medicine, Cell Proliferation, Positron-Emission Tomography, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.